<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5623">
  <stage>Registered</stage>
  <submitdate>22/05/2012</submitdate>
  <approvaldate>22/05/2012</approvaldate>
  <nctid>NCT01608087</nctid>
  <trial_identification>
    <studytitle>Pharmacokinetics and Safety Study of BI 695502 in Healthy Subjects</studytitle>
    <scientifictitle>Pharmacokinetics and Safety of BI 695502 in Healthy Subjects: a Randomized, Single-blind, Single-dose, Parallel-arm, Active-comparator Clinical Phase I Study</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>1302.1</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Healthy</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - BI 695502
Treatment: drugs - bevacizumab
Treatment: drugs - bevacizumab

Experimental: BI 695502 - Subject to receive one intravenous (i.v.) infusion of BI 695502

Active Comparator: bevacizumab A - Subject to receive one i.v. infusion of bevacizumab

Active Comparator: bevacizumab B - Subject to receive one i.v. infusion of bevacizumab


Treatment: drugs: BI 695502
BI 695502 single i.v. infusion

Treatment: drugs: bevacizumab
bevacizumab single i.v. infusion

Treatment: drugs: bevacizumab
bevacizumab single i.v. infusion

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity</outcome>
      <timepoint>up to 99 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point</outcome>
      <timepoint>up to 99 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Maximum measured concentration of the analyte in plasma</outcome>
      <timepoint>up to 99 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion criteria:

          1. Healthy males.

          2. Complete medical history, including physical examination, vital signs, 12-lead
             electrocardiogram (ECG), and clinical laboratory tests.

          3. Aged 21 to 50 years.

          4. Body mass index below or equal to 30.

          5. Body weight 65 to 95 kg, inclusive.</inclusivecriteria>
    <inclusiveminage>21</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>50</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Male</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria:

          1. Any finding of the medical examination (including blood pressure, pulse rate and ECG)
             deviating from normal and of clinical relevance.

          2. Any evidence of a clinically relevant concomitant disease, as judged by the
             investigator.

          3. History of relevant orthostatic hypotension, fainting spells, or blackouts.

          4. Chronic or relevant acute infections.

          5. History of relevant allergy/hypersensitivity (including allergy to the study
             medications or its excipients).

          6. Intake of prescribed or over-the-counter drugs within less than 6 half-lives of the
             respective drug prior to study drug administration or during the trial.

          7. Participation in another trial with a study medication within two months prior to
             administration or during the trial (six half-lives).

          8. Smoker (&gt; 10 cigarettes or &gt; 3 cigars or &gt; 3 pipes/day).

          9. Inability to refrain from smoking during days of confinement at the study center.

         10. Current alcohol abuse as judged by the investigator.

         11. Current drug abuse, as judged by the investigator.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/05/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>91</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/11/2012</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland NZ</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Boehringer Ingelheim</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This trial will investigate the pharmacokinetics and safety of BI 695502 and to establish
      pharmacokinetic biosimilarity of BI 695502 compared to bevacizumab.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01608087</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Boehringer Ingelheim</name>
      <address>Boehringer Ingelheim</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>